Transfer of brotizolam, periciazine, and sulpiride in cord blood and breast milk, and alprazolam in breast milk: a case report

Jumpei Saito 1*, Yoshiyuki Tachibana 2, Yuka Sano Wada 3, Naho Yakuwa 4, Hiroyo Kawasaki 1, Tomo Suzuki 5,6, Haruhiko Sago 6, Akimasa Yamatani 1,4 and Atsuko Murashima 4,5

Abstract

Background: A high prevalence of mental disorders including depression, anxiety, somatoform, and dissociative disorder is reported during pregnancy, however, information on the transfer of antipsychotics across the placenta and into breast milk is limited. We evaluated brotizolam, periciazine and sulpiride in cord blood, maternal serum, and breast milk, and alprazolam in breast milk.

Case presentation: A 38-year-old woman with dissociative disorder was treated with brotizolam, propericiazine, and sulpiride during pregnancy and lactation, and alprazolam during lactation. The drug concentration ratios for both cord blood and maternal serum were 33.3 and 61.5% for brotizolam and sulpiride, respectively, and periciazine (metabolite of propericiazine) was not detected in the cord blood. In breast milk, alprazolam (0.9 ng/mL), sulpiride (445.8 ng/mL), and periciazine (0.3 ng/mL) concentrations were noted at 7.5 h after the last dose on postpartum, whereas brotizolam was not detected. The relative infant doses via breast milk were 1.4, 2.7 and 0.02% of the maternal daily dose, respectively. The neonate had no congenital anomalies and did not experience any severe withdrawal symptoms after birth.

Conclusion: Use of brotizolam, propericiazine, and sulpiride during pregnancy and lactation, and use of alprazolam during lactation were acceptable in this case.

Keywords: Psychiatry, Psychotherapy, Pregnancy, Lactation

Background

A high prevalence of mental disorders including depression, anxiety, somatoform, and dissociative disorder is reported during pregnancy [1], and 10–25% of pregnant women with these disorders are prescribed antidepressants, such as benzodiazepines or benzodiazepine-like hypnotic drugs [2, 3], or antipsychotic drugs, such as phenothiazine-, butyrophenone-, and benzamide-derivative agents [4]. Benzodiazepines have been associated with increased risks of preterm birth, low Apgar score, and neonatal respiratory distress syndrome [5]. Although whether antipsychotic agents can affect pregnancy outcome is unclear [6], withdrawal symptoms in neonates exposed to antipsychotics during pregnancy have been reported [7]. However, information on placental or breastmilk transfer of these drugs is insufficient.

This report presents the case of a mother who used concomitant psychoactive drugs, including brotizolam, periciazine, sulpiride and zolpidem during the pregnancy and lactation, and alprazolam during lactation, and focuses on the outcomes for her neonate. The discussion addresses the safety of these drugs with reference to...
their concentrations in cord blood, maternal serum, and breast milk.

Case presentation
A 38-year-old woman (weight 40 kg) was evaluated for her first pregnancy. At age 28 years, she was diagnosed with dissociative disorder and persistent dysthymia depression, for which treatment with brotizolam (0.25 mg/day), propericiazine (10 mg/day), and zolpidem (5 mg/day) was initiated and continued during pregnancy. Propericiazine was initiated when she was 28 years old, and both brotizolam and zolpidem has been treated for five years.

At gestational week (GW) 28, zolpidem was discontinued. During GW 31, mirtazapine (15 mg/day) was initiated, but was discontinued after 2 weeks due to her symptoms of frustration and fatigue. During GW 33, sulpiride (100 mg/day) was initiated, and her depression and anxiety symptoms were slightly improved.

At GW 38, a healthy normal-birth-weight male neonate was delivered by Caesarean section. The Apgar scores at 1 and 5 min were both 8. No congenital anomalies were observed. Due to persistent post-natal respiratory distress, he was immediately administered oxygen with continuous positive airway pressure. At 4 h postpartum, tachypnea and vomiting developed. The total Neonatal Withdrawal Score was 3, based on the checklist by Isobe et al. [8], a simplified version of the Finnegan checklist that is widely used in Japan. No medicating or circulatory support was needed during admission.

Until discharge on postpartum day 7, the infant received both breastmilk and milk formula. Daily milk intake was ranged from 10 to 150 mL for pumped breastmilk and from 30 to 400 mL for milk formula. After discharge, he was bottle-fed formula without breastfeeding at least for 1 month. The mother continued taking brotizolam (0.25 mg/day), propericiazine (10 mg/day), and sulpiride (100 mg/day) postpartum, and alprazolam (0.4 mg/day) was initiated at postpartum day 5. However, at postpartum day 9, sulpiride was discontinued because galactorrhea due to hyperprolactinemia was noted, and sulpiride was replaced to paroxetine (10 mg/day) for treating her depression symptom. For her current anxiety symptoms, lorazepam (0.25 mg) was also initiated at postpartum day 18, as a daily treatment. At the 3-month postpartum health checkup, the infant had no detectable neurologic anomalies.

After ethics committee approval and receiving the mother’s written informed consent, cord blood, maternal serum, and breast milk were collected. Brotizolam, sulpiride, and periciazine (a metabolite of propericiazine) concentrations in maternal serum and breast milk, and alprazolam levels in breast milk were evaluated. The calibration curves for the assay were linear over the range of 0.1–50.0 ng/mL for alprazolam, brotizolam, and periciazine, and 1.0–500.0 ng/mL for sulpiride, and the lower limit of quantitation for each drug was 0.1 ng/mL for alprazolam, brotizolam, and periciazine, and 1.0 ng/mL for sulpiride. The intra-day precision expressed as coefficient of variation ranged from 2.7 to 9.8% for alprazolam, 1.4 to 8.2% for brotizolam, 0.8 to 8.1% for periciazine, and 3.1 to 8.9% for sulpiride. The inter-day precision values ranged from 2.9 to 9.6% for alprazolam, 1.5 to 8.6% for brotizolam, 3.2 to 9.1% for periciazine, and 3.2 to 8.9% for sulpiride. The accuracy values of the assay varied from 96.7 to 103.5% for alprazolam, 95.3 to 104.2% for brotizolam, 95.9 to 105.5% for periciazine, and 95.9 to 104.7% for sulpiride.

Table 1 shows the assay results. In cord blood collected immediately after delivery, brotizolam (0.1 ng/mL) and sulpiride (122.1 ng/mL) concentrations were detected at 19.1 h after each last dose, whereas no periciazine was detected (< 1.0 ng/mL).

In breast milk, alprazolam (0.9 ng/mL), sulpiride (445.8 ng/mL), and periciazine (0.3 ng/mL) concentrations were noted at 7.5 h after the last dose on postpartum day 9, whereas brotizolam was not detected. Although each level of the detected drug may not reflect the maximum concentration [9], and these calculations from one or two random milk levels are not justified, the calculated daily infant dose based on average breast milk intake (150 mL/kg/day) was 0.14 μg/kg/day for alprazolam, 66.9 μg/kg/day for sulpiride, and 0.05 μg/kg/day for periciazine. The relative infant doses via breast milk were 1.4, 2.7 and 0.02% of the maternal daily dose, respectively.

Discussion and conclusion
Brotizolam and sulpiride were detected in the cord blood after delivery. Previous studies reported that brotizolam was not detected in cord blood at 9.2 h after the last dose [10]; in our case, however, a small amount of brotizolam was detected, which parallels the findings for other benzodiazipines [11]. Sulpiride was also detected in the cord blood in our case, and this result agrees with a previous ex vivo study showing that a small amount of sulpiride may cross the human placenta and that several transporters are involved in the bidirectional transport of sulpiride between the placenta and fetal blood [12]. The penetration ratio for brotizolam and sulpiride, were calculated by dividing the concentrations in umbilical
cord blood by the maternal serum concentrations at the same time after the last dose (at approximately 19 h), was 33.3% (0.1/0.3) and 61.5% (122.1/198.5), respectively. However, these calculated values lack reliability because the values from the maternal serum samples collected at 17 days postpartum were used. Excretion of alprazolam was reported previously [13–15]. It should be noted that alprazolam concentrations in maternal serum were not considered at steady state, and an accurate transfer ratio of alprazolam into breast milk might not be determined.

Sulpiride has been found in breastmilk, and our result aligns with those in previous studies [9, 16, 17] and in a study on breastmilk secretion of amisulpride, a benzamide derivative with sulpiride [18]. Although brotizolam was secreted into breastmilk in previous study [10, 15], it was not detected in our study, possibly due to the different breastmilk sampling time.

Regarding pregnancy outcome, the mother received brotizolam and propericiazine during pregnancy, zolpidem from the first to second trimester, and sulpiride from GW 33 to delivery, with no evidence of congenital anomalies for the neonate. The neonatal withdrawal syndrome in our case was not severe, which was in line with the findings of previous observational study of neonates delivered by mothers taking psychotropic or anti-convulsant drugs [19].

Because neonates exposed to periciazine and benzodiazepines during the pregnancy are at increased risk of withdrawal symptoms at birth, in addition to neonatal agitation, hypertension, hypotonia, tremors, somnolence, and respiratory distress [11, 20], the causal relationship between use of these drugs during pregnancy and neonatal respiratory distress could not be ruled out.

This study has several limitations. First, we could not collect the breastmilk sample at the peak concentration of drugs (approximately 2 h after dose) [9, 15], and an accurate evaluation on maximum drug exposure could not be conducted. Second, the sampling number of maternal serum and breastmilk was small, and drug exposure could not be evaluated by using infant’s serum sample. Third, placental transfers of drugs were evaluated using the postpartum serum sample. Pharmacokinetic profiles of drugs during pregnancy and postpartum may differ; thus, further study is needed.

| Table 1 | Antipsychotic drug concentrations in serum and breast milk samples |
|---------|---------------------------------------------------------------|
| Drugs   | Sample types       | Postpartum days | Time after dose (hr) | Dose (mg) | Concentration(ng/mL) |
|---------|--------------------|-----------------|----------------------|-----------|----------------------|
| Brotizolam | Cord blood        | 0               | 19.1                 | 0.25      | 0.1                  |
|         | Mother serum      | 0               | 33.0                 | 0.25      | Below LOD            |
|         | Mother serum      | 5               | 7.5                  | 0.25      | 5.0                  |
|         | Mother serum      | 17              | 19.5                 | 0.25      | 0.3                  |
|         | Breast milk       | 9               | 7.5                  | 0.25      | Below LOD            |
|         | Breast milk       | 9               | 11.5                 | 0.25      | Below LOD            |
| Periciazine | Cord blood        | 0               | 19.1                 | 10        | Below LOD            |
|         | Mother serum      | 0               | 33.0                 | 10        | Below LOD            |
|         | Mother serum      | 5               | 7.5                  | 10        | 6.1                  |
|         | Mother serum      | 17              | 19.5                 | 10        | Below LOD            |
|         | Breast milk       | 9               | 7.5                  | 10        | 0.3                  |
|         | Breast milk       | 9               | 11.5                 | 10        | 0.1                  |
| Sulpiride | Cord blood        | 0               | 19.1                 | 100       | 122.1                |
|         | Mother serum      | 0               | 33.0                 | 100       | 63.9                 |
|         | Mother serum      | 5               | 7.5                  | 100       | 366.0                |
|         | Mother serum      | 17              | 19.5                 | 100       | 198.5                |
|         | Breast milk       | 9               | 7.5                  | 100       | 445.8                |
|         | Breast milk       | 9               | 11.5                 | 100       | 129.2                |
| Alprazolam | Cord blood        | 0               | –                    | 0         | Pre-dose             |
|         | Mother serum      | 0               | –                    | 0         | Pre-dose             |
|         | Mother serum      | 5               | 7.5                  | 0.4       | 2.3                  |
|         | Mother serum      | 17              | 19.5                 | 0.4       | 1.0                  |
|         | Breast milk       | 9               | 7.5                  | 0.4       | 0.9                  |
|         | Breast milk       | 9               | 11.5                 | 0.4       | 0.5                  |

LOD limit of detection
To the best of our knowledge, this report is the first describing the transfer of sulpiride and pericazcine across the placenta, and the first describing the transfer of pericazcine across the breastfeeding. Although antipsychotic drug use during pregnancy and lactation may have a certain risk for the fetus and breastfed infant, continuing antipsychotic medication may outweigh these risks if the mothers have uncontrolled psychotic symptoms. Further studies are needed to evaluate potentially harmful effects after exposure to benzodiazepines and antipsychotic drugs in utero and during breastfeeding.

Abbreviations
GW: Gestational week

Acknowledgments
We would like to thank Ms. Mariko Takagai for her administrative assistance. We are also grateful to the lactating mother for donating her precious breast milk.

Authors’ contributions
J.S., Y.T., Y.W., N.Y., H.K., T.S., H.S., and A.Y. were involved in the study. J.S. wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version.

Funding
This work was supported by National Center for Child Health and Development (NCCHD2021C-5) awarded to J.S. The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the ethics committee of the National Center for Child Health and Development (REC numbers: 2021–007). Written informed consent was obtained from the patient.

Consent for publication
Consent for publication was obtained from the patient.

Competing interests
A Murashima received research grant and lecture fee from Chugai Pharmaceutical, Co., Ltd. All other authors declare no conflicts of interest.

Each author has confirmed compliance with the journal’s requirements for authorship.

Author details
1 Department of Pharmacy, National Center for Child Health and Development, Tokyo, Japan. 2 Division of Infant and Toddler Mental Health, Department of Psychosocial Medicine, National Center for Child Health and Development, Tokyo, Japan. 3 Division of Neonatology, Center for Maternal-Fetal, Neonatal, and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan. 4 Division of Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan. 5 Division of Maternal Medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan. 6 Division of Obstetrics, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.

Received: 8 January 2022 Accepted: 15 March 2022
Published online: 01 April 2022

References
1. Wallwiener S, Goetz M, Lanfer A, Gillessen A, Suling M, Feist M, et al. Epidemiology of mental disorders during pregnancy and link to birth outcome: a large-scale retrospective observational database study including 38,000 pregnancies. Arch Gynecol Obstet. 2019;299:755–63. https://doi.org/10.1007/s00404-019-05075-2.
2. Lacroix I, Hurault C, Saramon MF, Guillard C, Berbebi A, Grau M, et al. Prescription of drugs during pregnancy: a study using EFMERS, the new French database. Eur J Clin Pharmacol. 2009;65:839–46. https://doi.org/10.1007/s00228-009-0647-2.
3. Hanley GE, Mintzes B. Patterns of psychotic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. BMC Pregnancy Childbirth. 2014;14:242. https://doi.org/10.1186/1471-2393-14-242.
4. Aliaqa A, Cunillera O, Amador MDC, Alagia M, Arquerons M, Almeda J. Association between affective disorders presenting before and during pregnancy and pre-term birth, considering socio-demographic factors, obstetric factors, health conditions, and use of medication. Atten Primaria. 2019;51:626–36. https://doi.org/10.1161/apem.2019.06.009.
5. Calderon-Margalit R, Qiu C, Ornoy A, Siscovick DS, Williams MA. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstet Gynecol. 2009;201:579.e1–579.e5.78. hhttps://doi.org/10.1016/j.ajog.2009.06.051.
6. Enarson A, McKenna K, Levinson A. Review: women with schizophrenia have poorer pregnancy outcomes than other women, but it is unclear whether antipsychotic medications affect their infants. Evid Based Ment Health. 2003;6:89. https://doi.org/10.1136/ebmh.6.3.89.
7. Conventino I, Sansone AC, Marino A, Balullo MT, Mantardo S, Antonioli L, et al. Neonatal adaptation issues after maternal exposure to prescription drugs: withdrawal syndromes and residual pharmacological effects. Drug Saf. 2016;39:903–34. https://doi.org/10.1007/s40264-016-0453-8.
8. Isobe K, Ishii M, Kusaka T. Research on systemic care system for a high risk child management of newborn babies with the withdrawal syndrome. Questionnaire survey on evaluation method by a check list and score table. 1995. https://www.nipg.go.jp/wadai/mnhw/1994/h061142.pdf. Accessed 20 Mar 2022.
9. Aono T, Shoji T, Ahi T, Hirotka K, Nomura A, Kurachi K. Augmentation of puerperal lactation by oral administration of sulpiride. J Clin Endocrinol Metab. 1979;48:478–82. https://doi.org/10.1210/jcem-48-3-478.
10. Saito J, Ishii M, Miura Y, Yakawa N, Kawasaki H, Suzuki T, et al. Brotizolam during pregnancy and lactation: Brotizolam levels in maternal serum, cord blood, breast milk, and neonatal serum. Breastfeed Med. 2021;16:579–82. https://doi.org/10.1089/bfm.2021.0013.
11. Iqbal MM, Sobhan T, Ryal T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv. 2002;53:39–49. https://doi.org/10.1176/appi.ps.53.1.39.
12. Bai M, Ma Z, Sun D, Zheng C, Weng Y, Yang X, et al. Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017;91:3873–84. https://doi.org/10.1007/s00204-017-1094-x.
13. Oo CY, Kuhn RJ, Dsai N, Wright CE, McNamara PJ. Pharmacokinetics in lactating women: prediction of alprazolam transfer into milk. Br J Clin Pharmacol. 1995;40:231–6. https://doi.org/10.1111/j.1365-2125.1995.tb05778.x.
14. Furugen A, Nishimura A, Kobayashi M, Umezame T, Narumi K, Ikeshi K. Quantification of eight benzodiazepines in human breast milk and plasma by liquid-liquid extraction and liquid-chromatography tandem mass spectrometry: application to evaluation of alprazolam transfer into breastmilk. J Pharm Biomed Anal. 2019;168:83–93. https://doi.org/10.1016/j.jpba.2019.02.011.
15. Nishimura A, Furugen A, Umezame T, Kitamura S, Sonma M, Noshiro K, et al. Benzodiazepine concentrations in the breast milk and plasma of nursing mothers: estimation of relative infant dose. Breastfeed Med. 2021;16:244–31. https://doi.org/10.1007/s11323-020-00529.
16. Ylikorkala O, Kauppi A, Kiviranta S, Pikkarainen S, Inkinen L. Sulpiride improves inadequate lactication. Br J Clin Res Ed. 1982;285:249–51. https://doi.org/10.1136/bmj.285.6337.249.
17. Ylikorkala O, Kauppi A, Kiviranta S, Pikkarainen S, Inkinen L. Treatment of inadequate lactation with oral sulpiride and buccal oxytocin. Obstet Gynecol. 1984;63:57–60.
18. SJ OH, Wong A, Joyce DA. A liquid chromatography-tandem mass spectrometry method for quantifying amisulpride in human plasma and breast milk, applied to measuring drug transfer to a fully breast-fed neonate. Ther Drug Monit. 2016;38:493–8. https://doi.org/10.1097/FTD.0000000000000300.

19. Kanemura A, Masamoto H, Kinjo T, Mekaru K, Yoshida T, Goya H, et al. Evaluation of neonatal withdrawal syndrome in neonates delivered by women taking psychotropic or anticonvulsant drugs: A retrospective chart review of the effects of multiple medications and breastfeeding. Eur J Obstet Gynecol Reprod Biol. 2020;254:226–30. https://doi.org/10.1016/j.ejogrb.2020.09.008.

20. Shyken JM, Babbar S, Babbar S, Forinash A. Benzodiazepines in Pregnancy. Clin Obstet Gynecol. 2019;62:156–67. https://doi.org/10.1097/GRF.0000000000000417.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.